Tumor News and Research

RSS

Women who undergo bilateral oophorectomy tend to have smaller tumors

More than half a million women in the United States undergo a hysterectomy each year and approximately half of those surgeries include removal of the ovaries. Researchers know that removing a woman's ovaries is associated with a reduction in the risk of developing breast cancer, but it has not been clear whether those cancers that do arise in these women differ from breast cancers in the general population.

29 May 2010

Patients with stage IIIA NSCLC who receive lobectomy have increased overall survival: Research

There's debate about the best treatment approach for patients with certain stages of non-small cell lung cancer, which accounts for about 80 percent of all lung cancers. Patients with early stages of NSCLC are typically treated with surgery, but those with stage IIIA present more of a challenge because they are such a diverse group.

29 May 2010

CytRx commences Phase 2 clinical trial of bafetinib for high-risk B-cell chronic lymphocytic leukemia

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced initiation of a Phase 2 proof-of-concept clinical trial to evaluate the preliminary efficacy and safety of its oncology drug candidate bafetinib in patients with high-risk B-cell chronic lymphocytic leukemia (B-CLL).

29 May 2010

LCRF to donate $25,000 for lung cancer studies at TGen

Following its first major Arizona fundraising event, the national Lung Cancer Research Foundation will donate $25,000 for lung cancer studies at the Translational Genomics Research Institute.

29 May 2010

Pancreatic cancer patients with circulating tumor cells tend to have worse outcomes: Study

Fox Chase Cancer Center investigators find that pancreatic cancer patients who have circulating tumor cells tend to have worse outcomes than patients without circulating tumor cells. Additionally, the team has uncovered evidence that not all circulating tumor cells are the same, and some may predict worse outcomes than others.

29 May 2010

Amorfix, Aragen Bioscience collaborate to develop high-affinity monoclonal antibodies against targets for cancer

Amorfix Life Sciences and Aragen Bioscience, Inc. announced today that they have entered into an agreement to develop high-affinity monoclonal antibodies against a number of targets for cancer. Using its proprietary ProMIS(TM) computational platform discovery technology, Amorfix has identified several disease specific epitopes ("DSEs") on misfolded Fas receptor. Aragen will use those DSEs to generate highly specific monoclonal antibodies ("mAbs").

28 May 2010

CytRx's bafetinib demonstrates significant inhibition of glioblastoma multiforme cell lines in preclinical trial

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that its drug candidate bafetinib (formerly known as INNO-406) demonstrated statistically significant inhibition of glioblastoma multiforme cell lines in a preclinical trial. Glioblastoma multiforme is the most common and aggressive primary adult brain tumor.

28 May 2010

Biomedical engineering professor receives Transition Career Development Award

Biomedical engineering professor David Zaharoff has been awarded a Transition Career Development Award by the National Cancer Institute to further his research on Interleukin-12, a powerful cytokine that shows great promise for therapeutic treatment of numerous types of cancer.

28 May 2010

Children's Hospital of Philadelphia announces availability of proton therapy at Roberts Proton Therapy Center

The Children's Hospital of Philadelphia announces the availability of proton therapy, a precise form of cancer radiation that offers potentially life-changing benefits to children with brain tumors and other solid tumors. The Hospital's Cancer Center has recently begun using proton treatment at the new Roberts Proton Therapy Center, a cutting-edge radiation oncology facility located across the street from Children's Hospital in Penn Medicine's Perelman Center for Advanced Medicine.

28 May 2010

The Wistar Institute Melanoma Research Center launched to develop new therapies for melanoma

In an effort to meet the rising rates of melanoma head-on, The Wistar Institute today announced the creation of The Wistar Institute Melanoma Research Center. The Center brings together scientists, physicians, the life sciences industry, and melanoma advocates in saving lives by advancing new and better therapies for this deadly disease.

28 May 2010

Positron Emission Mammography helps evaluate response to neoadjuvant chemotherapy: Study

In a recent study presented at the American Association of Cancer Research Annual Meeting in Washington, DC, researchers at the University of Texas MD Anderson Cancer Center showed that Positron Emission Mammography (PEM) helps evaluate response to neoadjuvant chemotherapy.

28 May 2010

YM BioSciences initiates enrollment in nimotuzumab trial in brain metastases from NSCLC

YM BioSciences Inc., today announced that the first US patient has been enrolled in its randomized, double-blind trial evaluating nimotuzumab in patients with brain metastases from NSCLC at the Florida Cancer Institute - New Hope. This trial initiation follows recent clearance from the US FDA announced on January 26, 2010 allowing the Company to enroll patients at US clinical sites for two of its international and ongoing randomized, double-blind Phase II trials of nimotuzumab.

27 May 2010

Genentech uses Complete Genomics' sequencing service to compare primary lung tumor, adjacent normal tissue

Complete Genomics Inc., a third-generation human genome sequencing company, today announced that Genentech Inc., a wholly owned member of the Roche Group, used the company's sequencing, bioinformatics and analytics services to sequence and compare a patient's primary lung tumor and adjacent normal tissue.

27 May 2010

Shark cartilage extract shows no benefit for patients with advanced non-small cell lung cancer

In the first scientific study of its kind, shark cartilage extract, AE-941 or Neovastat, has shown no benefit as a therapeutic agent when combined with chemotherapy and radiation for patients with advanced non-small cell lung cancer, according to researchers at The University of Texas MD Anderson Cancer Center.

27 May 2010

Blocking the activity of death receptor can stop tumor growth: New research study

Every cell contains machinery for self-destruction, used to induce death when damaged or sick. But according to a new research study, a receptor thought to mediate cell suicide in normal cells may actually be responsible for the unrestrained growth of cancerous tumors.

27 May 2010

Benefits of new health insurance reform law for Medicare recipients discussed in news conference

Speaker Nancy Pelosi, Health and Human Services Secretary Kathleen Sebelius, House Majority Leader Steny Hoyer, Barbara Kennelly of the National Committee to Preserve Social Security and Medicare, and Dr. Ben Williamowsky of Silver Spring, Md., a Medicare recipient, held a news conference today to discuss benefits of and misconceptions about the Affordable Care Act and Medicare.

27 May 2010

Modified measles virus may hold potential for treatment of medulloblastoma

The use of modified measles virus may represent a new treatment for a childhood brain tumor known as medulloblastoma, according to a new study appearing in Neuro-Oncology.

27 May 2010

New $1.4M study to develop novel computer automation techniques for reducing prep time of IMRT for cancer

Rensselaer Polytechnic Institute Professor Richard Radke is leading a new $1.4 million study to develop novel computer automation techniques that could reduce the prep time of a promising cancer-treatment technology from several hours to a few minutes.

27 May 2010

Highlights from June 2010 issue of American Journal of Pathology

Dr. Kanneboyina Nagaraju and colleagues at the Children's National Medical Center, Washington, DC demonstrate that affected muscle may directly contribute to inflammation in muscular dystrophy. Their report can be found in the June 2010 issue of The American Journal of Pathology.

26 May 2010

CEVEC, Pevion Biotech sign license option agreement for transient CAP-T cell expression technology

CEVEC Pharmaceuticals, the German developer of a novel human expression system derived from amniocytes, announced today the signing of an exclusive license option agreement with Pevion Biotech, the Swiss vaccine company. The agreement enables Pevion Biotech to exclusively use CEVEC's transient CAP-T™ cell expression technology to manufacture and commercialize a protein antigen for vaccination against a widespread human infectious disease.

26 May 2010

Tumor News and Research

Women who undergo bilateral oophorectomy tend to have smaller tumors

Patients with stage IIIA NSCLC who receive lobectomy have increased overall survival: Research

CytRx commences Phase 2 clinical trial of bafetinib for high-risk B-cell chronic lymphocytic leukemia

LCRF to donate $25,000 for lung cancer studies at TGen

Pancreatic cancer patients with circulating tumor cells tend to have worse outcomes: Study

Amorfix, Aragen Bioscience collaborate to develop high-affinity monoclonal antibodies against targets for cancer

CytRx's bafetinib demonstrates significant inhibition of glioblastoma multiforme cell lines in preclinical trial

Biomedical engineering professor receives Transition Career Development Award

Children's Hospital of Philadelphia announces availability of proton therapy at Roberts Proton Therapy Center

The Wistar Institute Melanoma Research Center launched to develop new therapies for melanoma

Positron Emission Mammography helps evaluate response to neoadjuvant chemotherapy: Study

YM BioSciences initiates enrollment in nimotuzumab trial in brain metastases from NSCLC

Genentech uses Complete Genomics' sequencing service to compare primary lung tumor, adjacent normal tissue

Shark cartilage extract shows no benefit for patients with advanced non-small cell lung cancer

Blocking the activity of death receptor can stop tumor growth: New research study

Benefits of new health insurance reform law for Medicare recipients discussed in news conference

Modified measles virus may hold potential for treatment of medulloblastoma

New $1.4M study to develop novel computer automation techniques for reducing prep time of IMRT for cancer

Highlights from June 2010 issue of American Journal of Pathology

CEVEC, Pevion Biotech sign license option agreement for transient CAP-T cell expression technology

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News